Adele Y. Wang
YOU?
Author Swipe
View article: Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors Open
Background Checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway are effective therapies in a range of immunogenic cancer types. Blocking this pathway with an oral therapy could…
View article: Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle
Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle Open
The programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint blockade is central to Immuno-Oncology based therapies, and alternatives to antibody blockers of this interaction are an active area of research due to antibody rel…
View article: T regulatory cell chemokine production mediates pathogenic T cell attraction and suppression
T regulatory cell chemokine production mediates pathogenic T cell attraction and suppression Open
T regulatory cells (Tregs) control immune homeostasis by preventing inappropriate responses to self and nonharmful foreign antigens. Tregs use multiple mechanisms to control immune responses, all of which require these cells to be near the…
View article: Novel Immune Check-Point Regulators in Tolerance Maintenance
Novel Immune Check-Point Regulators in Tolerance Maintenance Open
The great success of anti-cytotoxic lymphocyte antigen 4 (CTLA4) and anti-programed cell death protein 1 (PD1) in cancer treatment has encouraged more effort in harnessing the immune response through immunomodulatory molecules in various d…